First Clinical Medical College, Shanxi Medical University, Taiyuan, China.
Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, China.
Front Endocrinol (Lausanne). 2020 Sep 25;11:544752. doi: 10.3389/fendo.2020.544752. eCollection 2020.
This study aimed to investigate the characteristics and extent of glycometabolism impairment in patients with adrenal diseases, including Cushing syndrome, primary aldosteronism, pheochromocytoma, and nonfunctional adrenal incidentaloma.
This study enrolled thirty-two patients with adrenal diseases as adrenal disease groups and eight healthy individuals as healthy controls. Blood glucose levels were indicated by glucose concentration in interstitial fluid, which was documented using flash glucose monitoring system. According to flash glucose monitoring system data, parameters representing general blood glucose alterations, within-day and day-to-day glucose variability, and glucose-target-rate were calculated. Furthermore, blood glucose levels at nocturnal, fasting, and postprandial periods were analyzed. Besides, islet β-cell function and insulin resistance were assessed.
Analysis of flash glucose monitoring system-related parameters indicated impaired glycometabolism in patients with adrenal diseases compared with that of healthy controls at general blood glucose, within-day and day-to-day glucose variability, and glucose-target-rate levels. Furthermore, the dynamic glucose monitoring data revealed that significantly affected blood glucose levels compared with that of healthy controls were observed at postprandial periods in the Cushing syndrome and primary aldosteronism groups; at nocturnal, fasting and postprandial periods in the pheochromocytoma group. Significant insulin resistance and abnormal β-cell function were observed in the Cushing syndrome group compared with that in healthy controls.
Adrenal diseases can negatively affect glucose metabolism. Patients diagnosed with adrenal diseases should receive timely and appropriate treatment to avoid adverse cardiovascular events linked to hyperglycemia and insulin resistance.
本研究旨在探讨肾上腺疾病患者(包括库欣综合征、原发性醛固酮增多症、嗜铬细胞瘤和无功能性肾上腺意外瘤)糖代谢受损的特征和程度。
本研究纳入 32 例肾上腺疾病患者作为肾上腺疾病组,8 例健康个体作为健康对照组。血糖水平由间质液中的葡萄糖浓度表示,使用瞬态血糖监测系统记录。根据瞬态血糖监测系统数据,计算代表总体血糖变化、日内和日间血糖变异性以及血糖目标率的参数。此外,还分析了夜间、空腹和餐后的血糖水平。此外,评估了胰岛β细胞功能和胰岛素抵抗。
与健康对照组相比,肾上腺疾病患者的瞬态血糖监测系统相关参数分析显示其总体血糖、日内和日间血糖变异性以及血糖目标率水平的糖代谢受损。此外,动态血糖监测数据显示,库欣综合征和原发性醛固酮增多症组餐后血糖水平与健康对照组相比明显受到影响;嗜铬细胞瘤组夜间、空腹和餐后血糖水平均受到影响。与健康对照组相比,库欣综合征组存在明显的胰岛素抵抗和胰岛β细胞功能异常。
肾上腺疾病可对糖代谢产生负面影响。诊断为肾上腺疾病的患者应及时接受适当的治疗,以避免与高血糖和胰岛素抵抗相关的不良心血管事件。